ENALAPRIL HEPATOTOXICITY IN THE RAT - EFFECTS OF MODULATORS OF CYTOCHROME-P450 AND GLUTATHIONE

被引:16
作者
JURIMAROMET, M
HUANG, HS
机构
[1] Toxicology Section, Life Sciences Division, Health Protection Branch, Ottawa, Health and Welfare Canada
关键词
D O I
10.1016/0006-2952(92)90075-T
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of modulators of cytochrome P450 and reduced glutathione (GSH) on the hepatotoxicity of enalapril maleate (EN) were investigated in Fischer 344 rats. Twenty-four hours following the administration of EN (1.5 to 1.8 g/kg), increased serum transaminases (ALT and AST) and hepatic necrosis were observed. Pretreatment of the animals with pregnenolone-16alpha-carbonitrile, a selective inducer of the cytochrome P450IIIA gene subfamily, enhanced EN-induced hepatotoxicity. whereas pretreatment with the cytochrome P450 inhibitor, cobalt protoporphyrin, reduced the liver injury. Depletion of hepatic non-protein sulfhydryls (NPSHs), an indicator of GSH, by combined treatment with buthionine sulfoximine (BSO) and diethyl maleate (DEM) produced marked elevations in serum transaminases by 6 hr after EN treatment. Administered on its own, EN decreased hepatic NPSH content and when combined with the BSO/DEM pretreatment. the liver was nearly completely devoid of NPSHs. Protection from EN-induced hepatotoxicity was observed in animals administered L-2-oxothiazolidine-4-carboxylic acid, a cysteine precursor. Together, these observations suggest the involvement of cytochrome P450 in EN bioactivation and GSH in detoxification. The results corroborate previous in vitro observations pertaining to the mechanism of EN-induced cytotoxicity towards primary cultures of rat hepatocytes. Although the doses of EN used in this study were far in excess of therapeutic doses, under certain circumstances, this metabolism-mediated toxicologic mechanism could form the basis for idiosyncratic liver injury in patients receiving EN therapy.
引用
收藏
页码:1803 / 1810
页数:8
相关论文
共 35 条
[1]  
BASSO MAG, 1991, J APPL CARDIOL, V6, P401
[2]   DRUG-SPECIFIC ANTIBODIES IN PATIENTS RECEIVING CAPTOPRIL [J].
COLEMAN, JW ;
YEUNG, JHK ;
ROBERTS, DH ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (02) :161-165
[4]   TISSUE SULFHYDRYL GROUPS [J].
ELLMAN, GL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1959, 82 (01) :70-77
[5]   ENALAPRIL-INDUCED COUGH [J].
GIBSON, GR .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (12) :2701-2703
[6]   PREGNENOLONE 16-ALPHA-CARBONITRILE-INDUCIBLE P-450 GENE FAMILY - GENE CONVERSION AND DIFFERENTIAL REGULATION [J].
GONZALEZ, FJ ;
SONG, BJ ;
HARDWICK, JP .
MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (08) :2969-2976
[7]  
HELLIWELL TR, 1985, BRIT J EXP PATHOL, V66, P67
[8]  
IKEDA T, 1981, CHEM PHARM BULL, V29, P1416
[9]  
JAMES RC, 1982, J PHARMACOL EXP THER, V221, P708
[10]   HEPATIC GLUTATHIONE AND HEPATOTOXICITY - EFFECTS OF CYTOCHROME-P-450 COMPLEXING COMPOUNDS SKF 525-A, L-ALPHA ACETYLMETHADOL (LAAM), NORLAAM, AND PIPERONYL BUTOXIDE [J].
JAMES, RC ;
HARBISON, RD .
BIOCHEMICAL PHARMACOLOGY, 1982, 31 (10) :1829-1835